Related Experiment Videos

Cardiovascular disease in systemic lupus erythematosus: has the time for action come?

Sander I van Leuven1, John J P Kastelein, Michael R Hayden

  • 1Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

Current Opinion in Lipidology
|September 9, 2005
PubMed

Insights

Systemic lupus erythematosus (SLE) accelerates atherosclerosis, increasing cardiovascular disease risk beyond traditional factors. Disease-specific pathways are key to understanding and preventing this accelerated cardiovascular risk in SLE patients.

Area of Science:

  • Cardiovascular Science
  • Rheumatology
  • Immunology

Background:

  • Inflammation is a key characteristic of atherosclerotic disease.
  • Chronic inflammatory diseases, such as systemic lupus erythematosus (SLE), are linked to accelerated atherosclerosis.
  • SLE patients exhibit a higher incidence of cardiovascular disease (CVD).

Purpose of the Study:

  • To investigate the link between SLE and accelerated atherosclerosis.
  • To explore the etiological factors contributing to CVD in SLE patients.
  • To discuss disease-specific pathways and their impact on prevention strategies for SLE.

Main Methods:

  • Review of recent studies on cardiovascular disease markers in SLE patients.
  • Analysis of surrogate markers for CVD in SLE.
  • Identification and discussion of disease-specific risk factors in SLE.

Main Results:

  • Studies confirm an association between SLE and accelerated atherosclerosis.
  • Classical risk factors do not fully explain the increased CVD propensity in SLE.
  • Disease-specific pathways are identified as significant additional risk factors for CVD in SLE.

Conclusions:

  • Several disease-specific factors contribute to accelerated atherosclerosis in SLE.
  • Understanding these factors is crucial for developing future prevention strategies.
  • Targeting these pathways may mitigate cardiovascular risk in SLE patients.
Abstract

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...